MCID: MYL001
MIFTS: 49

Myelitis

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Myelitis

MalaCards integrated aliases for Myelitis:

Name: Myelitis 12 76 53 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:322
MeSH 44 D009187
NCIt 50 C26832
SNOMED-CT 68 41370002
UMLS 73 C0026975

Summaries for Myelitis

Disease Ontology : 12 A spinal cord disease that is characterized by inflammation of the white matter or gray matter of the spinal cord.

MalaCards based summary : Myelitis is related to acute transverse myelitis and transverse myelitis. An important gene associated with Myelitis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and lung, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Myelitis is inflammation of the spinal cord which can disrupt the normal responses from the brain to the... more...

Related Diseases for Myelitis

Diseases related to Myelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 acute transverse myelitis 33.9 AQP4 IL6
2 transverse myelitis 32.9 APOH AQP4 IL17A IL6 MBP TNF
3 neuromyelitis optica 31.7 AQP4 HLA-DPB1 IL17A IL6 MBP MOG
4 systemic lupus erythematosus 31.6 APOH HLA-DPB1 IL17A IL6 TNF
5 acute disseminated encephalomyelitis 30.9 AQP4 MBP MOG
6 arteriovenous fistula 30.2 APOH IL6
7 pneumonia 30.1 CCL11 IL6 TNF
8 neuritis 30.0 AQP4 MBP MOG TNF
9 optic neuritis 30.0 AQP4 MBP MOG TNF
10 lyme disease 29.9 IL17A IL6 TNF
11 rubella 29.8 HLA-DPB1 MOG TNF
12 spondylitis 29.8 IL17A IL6 TNF
13 mixed connective tissue disease 29.7 APOH IL6 TNF
14 hematopoietic stem cell transplantation 29.7 IL6 TNF
15 spinal cord injury 29.7 AQP4 IL6 TNF
16 optic nerve disease 29.7 AQP4 MBP MOG
17 colitis 29.7 IL17A IL6 TNF
18 intracranial hypertension 29.6 APOH AQP4 TNF
19 connective tissue disease 29.6 APOH HLA-DPB1 IL6 TNF
20 multiple sclerosis 29.6 AQP4 IL17A IL6 MBP MOG TNF
21 rheumatoid arthritis 29.5 HLA-DPB1 IL17A IL6 TNF
22 dermatitis, atopic 29.4 CCL11 IL17A IL9 TNF
23 localized scleroderma 29.3 IL6 TNF
24 psoriatic arthritis 29.3 IL17A IL6 TNF
25 ulcerative colitis 29.3 IL17A IL6 TNF
26 internuclear ophthalmoplegia 29.3 AQP4 MBP MOG
27 peripheral nervous system disease 29.2 AQP4 IL6 MBP MOG TNF
28 stroke, ischemic 29.2 APOH AQP4 MBP
29 narcolepsy 29.2 AQP4 HLA-DPB1 MOG TNF
30 demyelinating disease 29.1 AQP4 IL17A MBP MOG TNF
31 malaria 28.9 CCL11 IL17A IL6 IL9 TNF
32 viral encephalitis 28.9 IL6 MBP MOG TNF
33 asthma 28.7 CCL11 HLA-DPB1 IL17A IL6 IL9 TNF
34 acute flaccid myelitis 12.6
35 idiopathic acute transverse myelitis 12.3
36 secondary acute transverse myelitis 12.2
37 radiation myelitis 12.2
38 foix-alajouanine syndrome 11.6
39 antiphospholipid syndrome 11.4
40 thyrotoxic periodic paralysis 11.0
41 lupus - neurological sequelae 11.0
42 paresthesia 11.0
43 encephalitis 10.9
44 stiff-person syndrome 10.6
45 meningoencephalitis 10.6
46 lupus erythematosus 10.6
47 myelopathy, htlv-1-associated 10.5
48 tropical spastic paraparesis 10.5
49 meningitis 10.4
50 hepatitis 10.3

Graphical network of the top 20 diseases related to Myelitis:



Diseases related to Myelitis

Symptoms & Phenotypes for Myelitis

MGI Mouse Phenotypes related to Myelitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 AQP4 CCL11 IL17A IL6 IL9 MBP
2 immune system MP:0005387 9.23 AQP4 CCL11 IL17A IL6 IL9 MBP

Drugs & Therapeutics for Myelitis

Drugs for Myelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2 2921-57-5
8
Interferon beta-1a Approved, Investigational Phase 4,Phase 2 145258-61-3 6438354
9
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
10
Phenol Approved, Experimental Phase 4 108-95-2 996
11
Zinc sulfate Approved, Investigational Phase 4,Not Applicable 7733-02-0
12
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
13
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
14
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
15
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
16
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 1,Phase 2 2920-86-7
17 Antibodies, Blocking Phase 4
18 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
23 Hormones Phase 4,Phase 3,Phase 1,Phase 2
24 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
25 Antibiotics, Antitubercular Phase 4
26 Anti-Bacterial Agents Phase 4
27 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
29 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
30 Antitubercular Agents Phase 4
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
32 Topoisomerase Inhibitors Phase 4,Phase 1,Phase 2
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Analgesics Phase 4
35 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
37 Prednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2
38 Neuroprotective Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Methylprednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2
42 Interferon-beta Phase 4,Phase 2
43 Antiviral Agents Phase 4,Phase 2,Phase 3,Early Phase 1
44 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2
45 interferons Phase 4,Phase 2
46 Polymyxin B Phase 4
47 Polymyxins Phase 4
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
49 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
50 Micronutrients Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
4 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
5 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
6 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
7 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
8 Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Completed NCT02847026 Phase 4
9 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
10 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
11 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
12 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
13 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
14 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
15 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
16 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
17 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
18 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
19 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
20 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
21 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
22 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
23 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
24 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
25 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
26 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
27 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
28 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
29 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
30 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
31 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
32 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
33 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
34 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
35 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
36 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
37 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
38 Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study Recruiting NCT03722004 Phase 4
39 Duration of IPV Priming and Antibody Decay Recruiting NCT03202719 Phase 4
40 Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan Active, not recruiting NCT03286803 Phase 4
41 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Active, not recruiting NCT02853929 Phase 4
42 To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan Active, not recruiting NCT01908114 Phase 4
43 A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. Enrolling by invitation NCT03597919 Phase 4
44 Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China Enrolling by invitation NCT03546634 Phase 4
45 Persistence of IPV Immunity Not yet recruiting NCT03723837 Phase 4
46 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
47 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
48 Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns Unknown status NCT01870206 Phase 3
49 Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
50 Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 Completed NCT01604746 Phase 3

Search NIH Clinical Center for Myelitis

Cochrane evidence based reviews: myelitis

Genetic Tests for Myelitis

Anatomical Context for Myelitis

MalaCards organs/tissues related to Myelitis:

41
Spinal Cord, Brain, Lung, Bone, B Cells, T Cells, Bone Marrow

Publications for Myelitis

Articles related to Myelitis:

(show top 50) (show all 1280)
# Title Authors Year
1
Acute Transverse Myelitis in Children, Literature Review. ( 29696041 )
2018
2
Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. ( 29482893 )
2018
3
Acute transverse myelitis following an opsoclonus-myoclonus syndrome: An unusual presentation. ( 29773357 )
2018
4
The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation? ( 29386095 )
2018
5
Encephalitis and transverse myelitis in dengue and chikungunya coinfection. ( 29972580 )
2018
6
Drainage of Cerebrospinal Fluid and Blood Pressure Augmentation as Rescue Therapies for Ischemic Myelitis After Bronchial Embolization: A Case Report. ( 29851658 )
2018
7
Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders. ( 29789706 )
2018
8
Myelitis due to Coccidioidomycosis in an Immunocompetent Patient. ( 29808132 )
2018
9
Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. ( 29872583 )
2018
10
Acute Transverse Myelitis Caused by Echovirus 11 in a Pediatric Patient: Case Report and Review of the Current Literature. ( 29372173 )
2018
11
Acute myelitis of children with positive anti-GM1 antibody: Case series and literature review. ( 29768373 )
2018
12
Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. ( 29709797 )
2018
13
Two cases of sarcoidosis presenting as longitudinally extensive transverse myelitis. ( 29770929 )
2018
14
Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib. ( 29804266 )
2018
15
Neurosyphilis as a Cause of Transverse Myelitis in a Teenage Girl. ( 29602529 )
2018
16
Long-term outcomes of varicella zoster virus infection-related myelitis in 10 immunocompetent patients. ( 29957386 )
2018
17
Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. ( 29247071 )
2018
18
Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer. ( 29777943 )
2018
19
Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. ( 29655487 )
2018
20
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2018
21
Radiation-Induced Myelitis: Initial and Follow-Up MRI and Clinical Features in Patients at a Single Tertiary Care Institution during 20 Years. ( 29773568 )
2018
22
To start immune therapy or not? An unusual presentation of longitudinally extensive transverse myelitis with pyrexia. ( 29725838 )
2018
23
Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. ( 29249379 )
2018
24
MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. ( 29438836 )
2018
25
Myelitis and Polyradiculoneuropathy With Severe Pain: Unusual Neurological Manifestations as Presenting Symptoms of Brucellosis. ( 29953037 )
2018
26
Guillain-BarrAc syndrome, transverse myelitis and infectious diseases. ( 29375121 )
2018
27
Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. ( 29499441 )
2018
28
Hypereosinophilic atopic transverse myelitis. ( 29888734 )
2018
29
Familial monophasic acute transverse myelitis due to the pathogenic variant in <i>VPS37A</i>. ( 29473047 )
2018
30
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
31
Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. ( 29635997 )
2018
32
Longitudinally extensive transverse myelitis following dengue virus infection: A rare entity. ( 29536963 )
2018
33
CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. ( 29406923 )
2018
34
Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. ( 29710213 )
2018
35
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
36
Cytomegalovirus associated longitudinally extensive transverse myelitis and acute hepatitis in an immunocompetent adult. ( 29396069 )
2018
37
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018
38
Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015. ( 29028962 )
2018
39
Toxic Myelitis and Arachnoiditis After Intrathecal Delivery of Bupivacaine via an Implanted Drug Delivery System: Case Report and Review of the Literature. ( 29719742 )
2018
40
Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis. ( 29114566 )
2018
41
Effects of electroacupuncture on bladder and bowel function in patients with transverse myelitis: a prospective observational study. ( 29909400 )
2018
42
Longitudinally Extensive Transverse Myelitis. ( 29862450 )
2018
43
Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016. ( 30500056 )
2018
44
A neonatal mouse model of Enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis. ( 30503887 )
2018
45
Acute flaccid myelitis. ( 30510047 )
2018
46
US CDC task force to investigate acute flaccid myelitis cases. ( 30527604 )
2018
47
Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. ( 30077551 )
2018
48
Acute flaccid myelitis-Clustering of polio-like illness in the tertiary care centre in Southern India. ( 30169722 )
2018
49
Acute flaccid myelitis associated with enterovirus D68 infection: A case report. ( 30200066 )
2018
50
Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. ( 30225922 )
2018

Variations for Myelitis

Expression for Myelitis

Search GEO for disease gene expression data for Myelitis.

Pathways for Myelitis

Pathways related to Myelitis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 CCL11 HLA-DPB1 IL17A IL6 IL9 TNF
2
Show member pathways
13.08 CCL11 IL17A IL6 IL9 TNF
3
Show member pathways
12.54 CCL11 HLA-DPB1 IL17A IL6 IL9 TNF
4
Show member pathways
12.4 HLA-DPB1 IL17A IL6 TNF
5
Show member pathways
12.2 IL17A IL6 IL9 TNF
6 12.11 HLA-DPB1 IL6 TNF
7
Show member pathways
12.07 CCL11 IL17A IL6 TNF
8
Show member pathways
12.06 IL17A IL6 IL9 TNF
9 12.04 HLA-DPB1 IL6 TNF
10
Show member pathways
12 CCL11 IL6 TNF
11 11.99 AQP4 IL6 TNF
12
Show member pathways
11.88 CCL11 IL17A IL6 IL9
13
Show member pathways
11.87 IL17A IL6 TNF
14 11.78 AQP4 IL6 MBP TNF
15 11.73 CCL11 IL17A IL6 TNF
16 11.7 HLA-DPB1 IL6 TNF
17 11.59 IL17A IL9 TNF
18 11.51 HLA-DPB1 IL17A IL6 TNF
19 11.45 CCL11 IL6 TNF
20 11.31 CCL11 IL17A IL6 TNF
21 11.19 IL6 TNF
22 11.18 IL6 TNF
23 11.12 IL6 TNF
24 11.09 IL6 TNF
25 10.93 IL6 TNF
26 10.86 IL6 TNF
27 10.76 CCL11 IL17A IL6 IL9 TNF
28 10.58 CCL11 IL17A IL6 IL9 TNF
29 10.43 IL17A IL6 IL9 TNF

GO Terms for Myelitis

Cellular components related to Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 APOH HLA-DPB1 MBP TNF
2 extracellular space GO:0005615 9.43 APOH CCL11 IL17A IL6 IL9 TNF
3 external side of plasma membrane GO:0009897 8.92 AQP4 IL17A MOG TNF

Biological processes related to Myelitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.62 CCL11 IL17A IL6 TNF
2 regulation of signaling receptor activity GO:0010469 9.55 CCL11 IL17A IL6 IL9 TNF
3 negative regulation of neurogenesis GO:0050768 9.49 IL6 TNF
4 positive regulation of interleukin-6 secretion GO:2000778 9.48 IL17A MBP
5 positive regulation of osteoclast differentiation GO:0045672 9.46 IL17A TNF
6 positive regulation of chemokine production GO:0032722 9.43 IL6 TNF
7 positive regulation of glial cell proliferation GO:0060252 9.4 IL6 TNF
8 negative regulation of lipid storage GO:0010888 9.37 IL6 TNF
9 inflammatory response GO:0006954 9.35 CCL11 IL17A IL6 IL9 TNF
10 positive regulation of neuroinflammatory response GO:0150078 9.26 IL6 TNF
11 immune response GO:0006955 9.17 CCL11 HLA-DPB1 IL17A IL6 IL9 MBP

Molecular functions related to Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL11 IL17A IL6 IL9 TNF

Sources for Myelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....